Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

Engineered Delivery Systems for Chinese Herbal Medicine in Peripheral Nerve Regeneration: Challenges, Advances, and Future Perspectives

Zhang R., Gu M., Ma R., Li R., Xu S., Xu Z.

Narrative Review on Chronic Inflammation, published in Drug Des Devel Ther (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Drug Des Devel Ther (2025)
Reported sample size
—
Source database
Europe PMC
PMID
41281933
PMCID
PMC12640138
DOI
10.2147/dddt.s563805
Citations
1

Abstract (original English)

Peripheral neuropathy (PN), characterized by sensory, motor, and autonomic dysfunction, presents a significant therapeutic challenge owing to its diverse etiologies, dynamic spatiotemporal injury microenvironment, and impermeable blood-nerve barrier (BNB). The current treatment is mainly palliative and symptom-focused, and fails to solve the core pathological complexity, including the heterogeneity of nerve injury, the conflicting phases of inflammation, repair, and fibrosis, and the imbalance of the microenvironment in chronic conditions such as diabetes. Chinese herbal medicine (CHM) has multiple benefits including neuroprotective, anti-inflammatory, anti-oxidant, and microenvironmental regulation. However, its clinical translation is hindered by poor bioavailability, non-targeted biodistribution, BNB exclusion, and physicochemical mismatches in multicomponent formulations. Preclinical studies suggest that engineered delivery systems could emerge as a transformative solution to these limitations. Nanocarriers penetrate the BNB via diffusion or ligand-mediated targeting, offering spatiotemporal control through a stimulus-responsive design. Hydrogels align their degradation processes with nerve regeneration and correct the imbalanced microenvironments. Degradable membranes offer localized, sustained release, whereas functionalized nerve conduits address structural defects and i

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Peripheral NervesAnimalsHumansPeripheral Nervous System DiseasesDrugs, Chinese HerbalDrug Delivery SystemsNerve Regeneration

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research